Skip to content
About
Leadership
Executive Team
Board of Directors
Facilities
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Migraine
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
Lyme Disease
Mpox (Monkey Pox)
Smallpox
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-4800
TNX-801
TNX-4200 CD45
Rare Disease
TNX-2900
Expanded Access Policy
Medicines
Clinical Trials
News & Events
Press Releases
Tonix in the News
Tonix Sponsored News
Investor Presentations
Scientific Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Investor Presentations
Scientific Presentations
Program Specific Presentations
Conference Materials
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
June 2015
TNX-102 SL for Treatment of Fibromyalgia: Approaches to Pain Measurement
June 2015
TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization
August 2015
The (R)-isomer of isometheptene, decreases trigeminal sensitivity in the Inflammatory Soup and Spontaneous Trigeminal Allodynia rat models
August 2015
The AtEase Study: An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD
August 2015
(R)-isometheptene* (IMH) Binds to the Imidazoline-1 Receptor and (S)-IMH increases Blood Pressure: Potentially Superior Benefit-to-Risk Ratio for (R)-IMH as an Analgesic for Headache
November 2013
Cyclobenzaprine (CBP) and its Major Metabolite Norcyclobenzaprine (nCBP) are Potent Antagonists of the Serotonin Receptor 2A, Histamine H1 and α-Adrenergic Receptors: Mechanistic and Safety Implications…
Posts navigation
Newer posts